Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Lung Neoplasms 9Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Neoplasms 1

Interventions

Gemcitabine 21Cisplatin 16durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Taxes 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × Disulfides × Clear all
NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡